clinical trial · NCT07705555
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 960
Diabetic RetinopathyMacular EdemaMK-8748Aflibercept
brief summary
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person. The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.
started
Aug 27, 2026
primary completion
Oct 31, 2028
completion
Oct 31, 2029
last updated
Oct 1, 2026
official title
A Randomized, Double-Masked, Multicenter, 3-Arm, Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) MK-8748 Compared With Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol